Summary: Beacon Biosignals and Longboard Pharmaceuticals have formed a strategic partnership to study the relationship between sleep and neurological conditions, focusing initially on rare epileptic syndromes. The collaboration will use Beacon’s FDA-cleared Dreem 3S EEG headband and AI-driven neurobiomarkers to collect high-quality sleep data from patients’ homes. This partnership aims to enhance drug development and improve patient outcomes by integrating sleep data into the understanding and treatment of neurological conditions.
Key Takeaways:
- Beacon Biosignals and Longboard Pharmaceuticals are partnering to explore the impact of sleep on neurological conditions.
- The collaboration will utilize Beacon’s Dreem 3S EEG headband and AI-derived neurobiomarkers to collect and analyze sleep data.
- The initial focus will be on rare epileptic syndromes, aiming to improve patient outcomes and treatment effectiveness by incorporating sleep data.
Beacon Biosignals announced a strategic partnership with Longboard Pharmaceuticals Inc that combines Longboard’s drug development expertise with Beacon’s neurophysiological platform to develop a better understanding of the relationship between sleep and neurological conditions with an initial focus in rare epileptic syndromes.
“We spend a third of our lives sleeping, yet sleep has received little attention when assessing the patient profile in many neurological conditions. As a result, clinical development of therapies that impact the brain have historically ignored the critical physiology of sleep when assessing patient outcomes and treatment effectiveness,” says Jacob Donoghue, MD, PhD, CEO of Beacon Biosignals, in a release. “Our partnership with Longboard changes all of that. We’re excited to collaborate in studying the utility of sleep and factors that may impact the management of neurological conditions, particularly in rare epilepsies.”
The Beacon Platform offers tools to derive new insights for drug development and research. Initially, this collaboration will deploy Beacon’s FDA-cleared Dreem 3S EEG headband device and AI algorithm-derived neurobiomarkers to interrogate the neurophysiology of sleep longitudinally, at-scale, and from the comfort of a person’s home.
Collaboration Enhances Sleep Data Collection While Easing Patient Burden
This collaboration thereby enables Longboard to collect laboratory-quality sleep data while reducing the burden on patients and caregivers.
“Longboard is excited to partner with Beacon with the goal of pioneering a new era of research by leveraging innovative biomarker insights, approaches, and technology. Our hope is to apply data and key learnings obtained from our combined experience in clinical studies and EEG analyses to ultimately improve outcomes for patients and their families,” says Randall Kaye, MD, Longboard’s chief medical officer, in a release.
Photo 310386168 © Andrii Zorii | Dreamstime.com
Leave a Reply